1. The Vitamin K Cycle & Clotting Factors
Vitamin K is the essential cofactor for the enzyme gamma-glutamyl carboxylase. This enzyme is responsible for the post-translational modification of specific proteins, enabling them to bind calcium. In the liver, this process is critical for the activation of clotting factors **II (Prothrombin), VII, IX, and X**, as well as anticoagulant proteins **C and S**.
Clinically, Vitamin K exists in a cycle. Once it helps carboxylate a clotting factor, it becomes "spent" (epoxide form). The enzyme **Vitamin K Epoxide Reductase (VKOR)** then recycles it back to its active form. This is the exact enzyme targeted by Warfarin. By inhibiting VKOR, Warfarin starves the body of active Vitamin K, leading to anticoagulation.
2. VKDB: Preventing the "Silent" Neonatal Bleed
Vitamin K Deficiency Bleeding (VKDB), formerly known as "Hemorrhagic Disease of the Newborn," is a catastrophic but preventable condition. Neonates are born with virtually no Vitamin K stores because the molecule does not cross the placenta well, and breast milk is a poor source.
The Birth Shot Protocol
The **American Academy of Pediatrics (AAP)** and international pediatric societies mandate a single IM injection of Vitamin K1 within 6 hours of birth.
- Infants > 1500g: 1.0 mg IM.
- Infants ≤ 1500g: 0.5 mg IM.
3. Warfarin Reversal: ACCP & ASH Guidelines
In emergency medicine, the management of a high INR (International Normalized Ratio) requires a balance between reversal and the risk of thrombosis. According to the **American College of Chest Physicians (ACCP)**:
- INR 4.5 – 10.0 (No Bleeding): Routine Vitamin K is NOT recommended. Simply withhold Warfarin.
- INR > 10.0 (No Bleeding): 2.5mg to 5mg Oral Vitamin K1.
- Major Bleeding (Any INR): 5mg to 10mg IV Vitamin K1, administered slowly, alongside Prothrombin Complex Concentrate (PCC) or Fresh Frozen Plasma (FFP).
⚠️ Critical Safety: IV Phytonadione
Intravenous Vitamin K1 carries a boxed warning for Anaphylactoid Reactions. This is not a true IgE-mediated allergy but a reaction to the solubilizers (like polyethoxylated castor oil). To minimize risk, IV Vitamin K MUST be diluted in 50mL of saline/dextrose and infused over 20-30 minutes. NEVER give as an undiluted IV bolus.
4. Vitamin K1 (Phytonadione) vs. K2 (Menaquinone)
There is significant international confusion between K1 and K2.
Vitamin K1 (Phytonadione): Derived from green leafy vegetables. This is the form used for coagulation and emergency medicine.
Vitamin K2 (Menaquinone): Produced by gut bacteria and found in fermented foods. K2 is increasingly studied for its role in bone mineralization (activating osteocalcin) and preventing vascular calcification (activating Matrix Gla Protein). However, K2 is NOT used for INR reversal or VKDB prophylaxis.
5. Vitamin K Response Test in Liver Disease
In patients with cirrhosis and an elevated Prothrombin Time (PT), clinicians often perform a "Vitamin K Challenge." 10mg of Vitamin K is given IV for three days. If the PT improves, it suggests the coagulopathy was secondary to malabsorption (common in cholestatic liver disease). If the PT remains unchanged, it indicates severe hepatic biosynthetic failure, as the liver is no longer capable of utilizing the Vitamin K provided.
Conclusion
Vitamin K is a small molecule with a massive clinical footprint. From the delivery room to the emergency department, its role in preventing and stopping hemorrhage is unparalleled. This RxMedCalc tool provides clinicians with the evidence-based dosing required to navigate complex INR reversals and neonatal care with confidence and precision.